Equities analysts expect Adamas Pharmaceuticals Inc (NASDAQ:ADMS) to announce ($1.13) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Adamas Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.31) and the highest is ($1.07). Adamas Pharmaceuticals posted earnings per share of ($1.35) during the same quarter last year, which suggests a positive year over year growth rate of 16.3%. The company is scheduled to issue its next earnings results on Thursday, May 2nd.

On average, analysts expect that Adamas Pharmaceuticals will report full-year earnings of ($4.14) per share for the current fiscal year, with EPS estimates ranging from ($4.56) to ($3.65). For the next year, analysts anticipate that the firm will post earnings of ($2.23) per share, with EPS estimates ranging from ($2.65) to ($1.50). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Adamas Pharmaceuticals.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings results on Monday, March 4th. The specialty pharmaceutical company reported ($1.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.30. The firm had revenue of $13.32 million for the quarter, compared to analysts’ expectations of $13.30 million. Adamas Pharmaceuticals had a negative net margin of 384.77% and a negative return on equity of 101.46%.

A number of research analysts have weighed in on the stock. Zacks Investment Research cut shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 27th. HC Wainwright set a $40.00 price target on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, January 14th. BidaskClub raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, February 25th. Cowen cut shares of Adamas Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $30.00 to $15.00 in a research report on Tuesday, March 5th. Finally, Northland Securities reaffirmed a “buy” rating and set a $28.00 price target on shares of Adamas Pharmaceuticals in a research report on Tuesday, March 5th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $23.88.

In other news, CEO Gregory T. Went sold 6,319 shares of the business’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $7.99, for a total transaction of $50,488.81. Following the transaction, the chief executive officer now directly owns 176,291 shares of the company’s stock, valued at $1,408,565.09. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders have sold 8,361 shares of company stock worth $66,816. Corporate insiders own 24.60% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Deutsche Bank AG lifted its position in shares of Adamas Pharmaceuticals by 506.7% during the fourth quarter. Deutsche Bank AG now owns 274,050 shares of the specialty pharmaceutical company’s stock worth $2,339,000 after purchasing an additional 228,883 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Adamas Pharmaceuticals by 31.0% during the fourth quarter. American Century Companies Inc. now owns 163,992 shares of the specialty pharmaceutical company’s stock worth $1,400,000 after purchasing an additional 38,779 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Adamas Pharmaceuticals by 6.8% during the fourth quarter. Geode Capital Management LLC now owns 232,900 shares of the specialty pharmaceutical company’s stock worth $1,988,000 after purchasing an additional 14,902 shares in the last quarter. Millennium Management LLC lifted its position in shares of Adamas Pharmaceuticals by 91.6% during the fourth quarter. Millennium Management LLC now owns 479,899 shares of the specialty pharmaceutical company’s stock worth $4,098,000 after purchasing an additional 229,404 shares in the last quarter. Finally, Macquarie Group Ltd. lifted its position in shares of Adamas Pharmaceuticals by 51.7% during the fourth quarter. Macquarie Group Ltd. now owns 2,708,217 shares of the specialty pharmaceutical company’s stock worth $23,128,000 after purchasing an additional 923,099 shares in the last quarter. 88.28% of the stock is currently owned by institutional investors and hedge funds.

ADMS stock traded down $0.01 during midday trading on Wednesday, reaching $6.43. 333,522 shares of the company’s stock traded hands, compared to its average volume of 573,986. The stock has a market cap of $175.41 million, a price-to-earnings ratio of -1.32 and a beta of 1.43. The company has a quick ratio of 9.20, a current ratio of 9.41 and a debt-to-equity ratio of 1.31. Adamas Pharmaceuticals has a fifty-two week low of $6.22 and a fifty-two week high of $32.90.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Featured Article: S&P 500 Index

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.